In the second quarter of 2026, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests, including:

• BARQ | BCR::ABL1, Rare Fusion Monitoring, Quantitative, Varies
  • Quantitatively monitors rare BCR::ABL1 fusion transcript types in myeloid neoplasms and B-cell acute lymphoblastic leukemia.
  • Enables treatment response monitoring for patients with uncommon BCR::ABL1 transcript variants not assessable by standard p190 or p210 assays.
  • Utilizes droplet digital PCR technology for sensitive detection and quantification.
  • Supports individualized disease monitoring and clinical management.
• CD123 | CD123 Immunostain, Technical Component Only
  • Identifies CD123 expression in plasmacytoid monocytes, mast cells, megakaryocytes, and hematopoietic precursors.
  • Aids in the characterization of hematologic and lymphoid disorders.
  • Helps distinguish blastic plasmacytoid dendritic cell neoplasm from other malignancies, including acute monocytic leukemia.
• DMTBR | Mycobacterium tuberculosis Complex, Molecular Detection of Drug Resistance Markers, Next-Generation Sequencing
  • Detects genetic markers associated with drug resistance in Mycobacterium tuberculosis complex isolates.
  • Provides more rapid identification of resistance-associated variants than traditional phenotypic susceptibility testing for selected targets.
  • Helps resolve discrepant results between molecular and culture-based testing methods.
  • Supports testing of isolates that are not sufficiently viable for culture-based drug susceptibility testing.
• DMAID | Mycobacterium abscessus Complex Subspecies Identification, Next-Generation Sequencing
  • Determines the subspecies of Mycobacterium abscessus complex culture isolates.
  • Supports treatment decisions by identifying subspecies with differing macrolide susceptibility profiles.
  • Assists epidemiologic investigations and patient management through enhanced organism characterization.
• SLA | Soluble Liver Antigen (SLA) IgG Antibodies, Serum
  • Evaluates patients at risk for autoimmune hepatitis or liver disease of unknown cause.
  • Detects anti-SLA antibodies, one of the most specific serologic markers for autoimmune hepatitis.
  • Helps identify autoimmune hepatitis in patients who may be negative for traditional autoantibodies.
  • Supports diagnosis of cryptogenic hepatitis and autoimmune liver disease overlap syndromes.
• TAPNS | Tapentadol and Metabolite, Serum
  • Monitors compliance in patients prescribed tapentadol therapy.
  • Detects and measures tapentadol and its primary metabolite, N-desmethyltapentadol.
  • Supports therapeutic monitoring and medication adherence assessment in pain management.

Visit our test catalog for more information on new or updated tests and testing algorithms.